TScan Therapeutics, Inc.TCRXNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank83
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
-1.00
↑ 82% vs avg
Percentile
P83
Within normal range
Streak
2 yr
Consecutive growthElevated
Average
-5.70
Historical baseline
PeriodValueYoY Change
2025-1.00+62.5%
2024-2.67+37.7%
2023-4.29-661.6%
2022-0.56+74.6%
2021-2.21+77.9%
2020-10.02+47.7%
2019-19.17-